Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
NCT00464776 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2011-02-04
Summary
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
Aliskiren
- DRUG
-
Aliskiren
- DRUG
-
Aliskiren
- DRUG
-
Aliskiren
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Investigative site
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 30 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2008-04-30
Countries
- Denmark
Study Locations
More Related Trials
-
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
NCT00787605 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
NCT00927394 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
NCT01259297 ·Status: TERMINATED ·Phase: PHASE3
-
The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome
NCT01432106 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
NCT00219167 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan
NCT01409408 ·Status: WITHDRAWN ·Phase: PHASE4
-
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
NCT00416728 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
NCT00416468 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
NCT00853658 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)
NCT00856960 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
NCT00417170 ·Status: COMPLETED ·Phase: PHASE2
-
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00654875 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
NCT00772577 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
NCT00819767 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
NCT00706134 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
NCT00441064 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
NCT00219076 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients
NCT01048047 ·Status: UNKNOWN ·Phase: PHASE4